Abstract
Only a third of immune-associated loci from genome-wide association studies (GWAS) colocalize with expression quantitative trait loci (eQTLs). To learn about causal genes and mechanisms at the remaining loci, we created a unified single-cell chromatin accessibility (scATAC-seq) map in peripheral blood comprising a total of 282,424 cells from 48 individuals. Clustering and topic modeling of scATAC data identified discrete cell-types and continuous cell states, which helped reveal disease-relevant cellular contexts, and allowed mapping of genetic effects on chromatin accessibility across these contexts. We identified 37,390 chromatin accessibility QTLs (caQTL) at 10% FDR across eight cell groups and observed extensive sharing of caQTLs across immune cell contexts, finding that fewer than 20% of caQTLs are specific to a single cell type. Notably, caQTLs colocalized with ∼50% more GWAS loci compared to eQTLs, helping to nominate putative causal genes for many unexplained loci. However, most GWAS-caQTL colocalizations had no detectable downstream regulatory effects on gene expression levels in the same cell type. We find evidence that the higher rates of colocalization between caQTLs and GWAS signals reflect missing disease-relevant cellular contexts among existing eQTL studies. Thus, there remains a pressing need for identifying disease-causing cellular contexts and for mapping gene regulatory variation in these cells.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Institute of Health grants R35GM153249 (Y.I.L.), R01GM130738 (Z.M, Y.I.L), R01GM134376 (L.B.B.) and R35GM152227 (L.B.B.). This work was also supported by Canadian Institutes of Health Research grants VR2-173203 and 178344 to D.E.K. We also acknowledge the support from the UChicago DDRCC, Center for Interdisciplinary Study of Inflammatory Intestinal Disorders(C-IID) (NIDDK P30 DK042086). H.E.R. was supported by a Ruth L. Kirschstein National Research Service Award (NHLBI F31-HL156419). The Biobanque Quebecoise de la COVID-19 (BQC19) is supported by the FRQS Genome Quebec and the Public Health Agency of Canada. L.B.B. and Y.I.L. are CZ Biohub Investigators.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Centre Hospitalier de l Universite de Montreal institutional ethics board gave ethical approval for this work: MP-02-2020-8929.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors after final publication of the article.
